Migraine is a complex neurologic event encompassing moderate to severe headache as well as systemic and neurologic symptoms. Treatment is aimed at both amelioration of symptoms as well as prevention of attacks. Dosage below is based on the Lancet (2018) review and International Headache Society (IHS) guidelines but may vary based on a patient’s medical and clinical circumstances.
Note: The FDA has approved medications for treatment of migraine with and without aura, based on new classes of drugs (see ‘Primary Sources – Learn More’ below)
Notes: (Canadian Headache Society Guidelines)
Treatment of migraines is intended to reduce the acute symptoms as well as prevent future events. A multitude of medical therapies are available to this end. When starting therapy begin with the lowest dose and escalate slowly. A 2-3 month trial is necessary to determine efficacy. 6 months may be needed to achieve maximal result.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (2018).
Mother To Baby: Sumatriptan Fact Sheet
FDA HIGHLIGHTS OF PRESCRIBING INFORMATION: UBRELVY (ubrogepant)
AAFP: Approach to Acute Headache in Adults
Please log in to ObGFirst to access the 2T US Atlas